08:00 AM EDT, 05/29/2025 (MT Newswires) -- Keros Therapeutics ( KROS ) said Thursday that it will discontinue the development of cibotercept in pulmonary arterial hypertension and cut its workforce by about 45% as part of its corporate restructuring.

The job cuts will start after the mandated 60-day notice period and will leave the company with 85 full-time employees, according to the statement. Keros estimates the actions to yield about $17 million in annualized cost savings.

Meanwhile, Keros said the decision to discontinue cibotercept was based on its analysis of the results of cibotercept's phase 2 trial in pulmonary arterial hypertension and that it plans to still evaluate the "appropriate" strategy for cibotercept in other indications after completing a review of strategic options.

Keros also said its strategic review continues, with options such as the company's sale being considered. The company expects to issue a preliminary update on the review process no later than June 9.